PRE1BRAZIL Protocol: A Randomized Controlled Trial to Evaluate the Effectiveness and Safety of the DPP-4 Inhibitor Alogliptin in Delaying the Progression of Stage 2 Type 1 Diabetes
Jaquellyne Penaforte-Saboia,Carlos Couri,Natasha Albuquerque,Lana Linard,Daniel Araújo,Sherida de Oliveira,Thisciane Gomes,Marcelo Pinheiro,Maria Castelo,Virgínia Fernandes,Renan Montenegro Júnior
DOI: https://doi.org/10.2147/dmso.s437635
2024-02-21
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Jaquellyne Gurgel Penaforte-Saboia, 1, 2, &ast Carlos Eduardo Barra Couri, 3, &ast Natasha Vasconcelos Albuquerque, 2, 4, &ast Lana Livia Peixoto Linard, 1, 2, &ast Daniel Autran Cavalcante Araújo, 5, &ast Sherida Karanini Paz de Oliveira, 6 Thisciane Ferreira Pinto Gomes, 2 Marcelo Maia Pinheiro, 7 Maria Helane Costa Gurgel Castelo, 2 Virgínia Oliveira Fernandes, 2, 4 Renan Magalhães Montenegro Júnior 1, 2, 4, &ast 1 Department of Clinical Medicine, Federal University of Ceará, Fortaleza, CE, Brazil; 2 Clinical Research Unit, Walter Cantídio University Hospital, Federal University of Ceará/ EBSERH Fortaleza, Fortaleza, CE, Brazil; 3 Center for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto, Ribeirão Preto School of Medicine, University of São Paulo, Ribeirão Preto, SP, Brazil; 4 Department of Community Health, Federal University of Ceará, Fortaleza, CE, Brazil; 5 Department of Internal Medicine, Sinai Grace Hospital/Detroit Medical Center, Detroit, MI, USA; 6 Ceará State University, Fortaleza, CE, Brazil; 7 UNIVAG, University Center, Faculty of Medicine, Várzea Grande, Mato Grosso, Brazil &astThese authors contributed equally to this work Correspondence: Renan Magalhães Montenegro Júnior, Hospital Complex (CH) of UFC/EBSERH, Rua Coronel Nunes de Melo 1142, Fortaleza, Ceará, 60430-270, Brazil, Tel +55 8533668600, Fax +55 8533668619, Email Background: The incidence of Type 1 Diabetes Mellitus (T1DM) is on the rise. Since there is no curative treatment, it is urgent to look for therapies that can delay disease progression and protect pancreatic β-cells. Dipeptidyl peptidase-4 inhibitors (DPP-4i) have shown potential in modulating inflammation and preventing β-cell destruction. This protocol describes an upcoming trial to evaluate the effectiveness of the DPP-4i alogliptin in delaying the progression of stage 2 (presymptomatic) to stage 3 (symptomatic) T1DM. Patients and Methods: We propose a two-year, two-arm, multicenter, randomized, open-label clinical trial targeting Brazilian patients aged 18 to 35 with stage 2 T1DM. The study, facilitated by the custom-developed "PRE1BRAZIL" web application, aims to enroll 130 participants. They will be randomly assigned in a 1:1 ratio to either a treatment group (alogliptin 25 mg daily plus regular clinical and laboratory assessments) or a control group (regular assessments only). The primary outcome is the rate of progression to stage 3 T1DM. Secondary outcomes include changes in A1c levels, glucose levels during a 2-hour oral glucose tolerance test (OGTT), C-peptide levels, exogenous insulin requirements, Insulin-Dose Adjusted A1c (IDAA1c), and the incidence of diabetic ketoacidosis (DKA) in those advancing to stage 3. Discussion: This protocol outlines the first randomized clinical trial (RCT) to investigate the impact of a DPP-4i in the presymptomatic stage of T1DM. The trial is designed to provide critical insights into the role of DPP-4i in the secondary prevention of T1DM. Utilizing the "PRE1BRAZIL" web application is expected to enhance participant enrollment and reduce operational costs. Registration: Brazilian Registry of Clinical Trials. Keywords: type 1 diabetes, web applications, DPP-4i, stage 2 T1DM, clinical trial protocol The incidence of Type 1 Diabetes Mellitus (T1DM) is rising at an alarming rate globally. Currently, over 1.2 million children and adolescents are living with T1DM 1 and the worldwide prevalence is estimated at over 46 million. 2 In Brazil, it is projected that the prevalence of diabetes will rise from 8.5% to 9.9% within the next three decades; and T1DM represents 10–15% of all Diabetes Mellitus (DM) etiologies. 1 The economic burden per case of DM is greater for T1DM than for type 2 diabetes (T2DM) and data suggest that the annual direct and indirect costs secondary to T1DM amount to US$ 14.4 billion. 3 T1DM develops due to a combination of genetic susceptibility and environmental factors, leading to autoimmunity, inflammation, and destruction of insulin-producing pancreatic β-cells. 4 The presence of one or more specific autoantibodies, such as insulin autoantibodies (IAA), glutamic acid decarboxylase antibodies (GAD), protein tyrosine phosphatase islet antigen-2 (IA2), and zinc transporter 8 (ZnT8) is a hallmark of T1DM. These autoantibodies serve as early indicators of β-cell autoimmunity and are crucial in identifying individuals at risk of progressing -Abstract Truncated-
endocrinology & metabolism